Cardiff University researchers have been awarded a £2.3 million Development Pathway Funding Scheme grant from the Medical Research Council (MRC) to advance the development of an innovative approach to treating acute myeloid leukaemia.The award will f
NICE recommends injectable BsAb for aggressive blood cancer europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase III trial has found.
Autolus Therapeutics (AUTL) Presents Clinical Data Updates streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
<p>Leukaemia trial shows 'exceptional' resultsPersonalised treatment for the most common form of adult leukaemia helps patients survive for longer and stay in remission, a phase III trial has found.</p>
<p>Adult patients were given a combination of cancer growth blocking drugs over varied durations depending on how rapidly their disease responded. </p>
<p>More than 19 in 20 patients were in remission three years after starting treatment - a significant improvement in progression-free and overall survival compared to standard treatment.</p>
<p>Study lead Professor Peter Hillmen said: “The results of the FLAIR Trial, led by the Leeds Cancer Research UK Clinical Trials Unit at the University of Leeds, are exceptional and herald a change in the way chronic lymphocytic leukaemia will be treated.”</p>